Danièle Ouellet

11.0k total citations · 1 hit paper
93 papers, 3.3k citations indexed

About

Danièle Ouellet is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Danièle Ouellet has authored 93 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 26 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Danièle Ouellet's work include Melanoma and MAPK Pathways (13 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Statistical Methods in Clinical Trials (11 papers). Danièle Ouellet is often cited by papers focused on Melanoma and MAPK Pathways (13 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Statistical Methods in Clinical Trials (11 papers). Danièle Ouellet collaborates with scholars based in United States, Belgium and United Kingdom. Danièle Ouellet's co-authors include Jeffrey R. Infante, Richard Kefford, Georgina V. Long, Michael Millward, Anna C. Pavlick, Kevin B. Kim, Samuel C. Blackman, Peter F. Lebowitz, Razelle Kurzrock and Gary M. Pollack and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Danièle Ouellet

90 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →

Peers

Countries citing papers authored by Danièle Ouellet

Since Specialization

Citations

This map shows the geographic impact of Danièle Ouellet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danièle Ouellet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danièle Ouellet more than expected).

Fields of papers citing papers by Danièle Ouellet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danièle Ouellet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danièle Ouellet. The network helps show where Danièle Ouellet may publish in the future.

Co-authorship network of co-authors of Danièle Ouellet

This figure shows the co-authorship network connecting the top 25 collaborators of Danièle Ouellet. A scholar is included among the top collaborators of Danièle Ouellet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danièle Ouellet. Danièle Ouellet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma 2025 ·Clinical and Translational Science ·(unknown), Jerry Li, (unknown), Dana J. Nickens, Danièle Ouellet, Mohamed H. Shahin	0
2	Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation 2024 ·Clinical Pharmacokinetics ·Alex Yu, Anasuya Hazra, James Jiao, Peter Hellemans, (unknown), Hui Tian, Juan José Pérez Ruixo, Nahor Haddish‐Berhane, Danièle Ouellet, Alberto Russu	1
3	Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model 2024 ·Targeted Oncology ·(unknown), (unknown), Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Loeckie De Zwart, Suzette Girgis, Xuewen Ma, Danièle Ouellet	1
4	Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma 2022 ·Cancer Chemotherapy and Pharmacology ·Anne‐Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Narayan Avadhani, Anne O’Hagan, Lilian Y. Li, Danièle Ouellet, Juan José Pérez Ruixo	7
5	Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre, Anjali Narayan Avadhani, Anne O’Hagan, Lilian Y. Li, Danièle Ouellet, (unknown), (unknown), Italo Poggesi, Juan José Pérez Ruixo	10
6	Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer 2020 ·Clinical Cancer Research ·(unknown), (unknown), Danièle Ouellet, Caly Chien, Hiroji Uemura, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Margaret K. Yu, Juan José Pérez Ruixo, Matthew R. Smith, Eric J. Small	17
7	Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors 2019 ·Cancer Chemotherapy and Pharmacology ·Elodie Valade, Anne‐Gaëlle Dosne, Hong Xie, Robert Kleiman, Lilian Y. Li, Juan José Pérez Ruixo, Danièle Ouellet	7
8	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) 2014 ·Clinical Cancer Research ·Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, (unknown), (unknown), Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Melvin Chin, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford	51
9	A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D) 2014 ·Clinical Pharmacology & Therapeutics ·Benjamin Suttle, Kenneth F. Grossmann, (unknown), Danièle Ouellet, Gursel Aktan, (unknown), Patricia LoRusso, (unknown), Shilpy Sharma, Kari Kendra, (unknown), Shubham Pant, Hendrik-Tobias Arkenau, Mark R. Middleton, (unknown), Stanley W. Carson	3
10	Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites 2014 ·The Journal of Clinical Pharmacology ·Danièle Ouellet, Ekaterina Gibiansky, (unknown), Anne O’Hagan, Patricia Haney, Julie Switzky, Vicki Goodman	57
11	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor 2012 ·Journal of Clinical Oncology ·Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis	356
12	Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura 2010 ·The Journal of Clinical Pharmacology ·Ekaterina Gibiansky, Jianping Zhang, (unknown), Zhao Wang, Danièle Ouellet	75
13	Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing 2010 ·The Journal of Clinical Pharmacology ·(unknown), Danièle Ouellet, Jianping Zhang, Mary Beth Wire, Ekaterina Gibiansky	32
14	The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment 2008 ·Clinical Pharmacology & Therapeutics ·Danièle Ouellet, J.L. Werth, (unknown), Douglas E. Feltner, (unknown), (unknown)	20
15	How Modeling and Simulation Have Enhanced Decision Making in New Drug Development 2005 ·Journal of Pharmacokinetics and Pharmacodynamics ·Raymond Miller, Wayne Ewy, Brian Corrigan, Danièle Ouellet, David Hermann, Kenneth G. Kowalski, Peter Lockwood, Jeffrey R. Koup, Sean D. Donevan, Ayman El‐Kattan, (unknown), John L. Werth, Douglas E. Feltner, Richard L. Lalonde	99
16	Pharmacokinetics of Quinapril in Children: Assessment during Substitution for Chronic Angiotensin‐Converting Enzyme Inhibitor Treatment 2003 ·The Journal of Clinical Pharmacology ·Jeffrey L. Blumer, Stephen R. Daniels, William J. Dreyer, Donald L. Batisky, Philip D. Walson, (unknown), Danièle Ouellet	17
17	Single‐Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children 2001 ·The Journal of Clinical Pharmacology ·George M. Haig, Howard N. Bockbrader, David Wesche, Samuel W. Boellner, Danièle Ouellet, R. R. Brown, Edward J. Randinitis, Edward L. Posvar	58
18	Comparison of Different Methods to Evaluate Population Dose–Response and Relative Potency: Importance of Interoccasion Variability 1999 ·Journal of Pharmacokinetics and Biopharmaceutics ·(unknown), Danièle Ouellet, Ebi K. Kimanani, Diane Potvin, Leigh M. Vaughan, Malcolm Hill	9
19	Pharmacokinetic interaction between ritonavir and clarithromycin* 1998 ·Clinical Pharmacology & Therapeutics ·Danièle Ouellet, Ann Hsu, G. Richard Granneman, Glenn Carlson, John H. Cavanaugh, (unknown), John M. Leonard	64
20	Focal ectasia of the terminal bowel accompanying low anal deformities 1987 ·Journal of Pediatric Surgery ·(unknown), (unknown), (unknown), (unknown), Danièle Ouellet	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact